Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

While GLP-1 drugs are currently available in the market, the Food and Drug Administration (FDA) had declared a shortage of semaglutide supply since 2022 after its popularity skyrocketed following news ...

Hims & Hers turned in tremendous revenue and profitability growth in the fourth quarter. The company also issued very robust guidance. However, it will stop selling semaglutide-based weight-loss ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims & Hers(NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty ...

Kathy Hochul to reverse course on a recently passed state law that shields the identities of healthcare providers who prescribe and mail the abortion pill mifepristone. In a letter to Hochul on ...

Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other stocks that grow firmer despite mixed market sentiment. The stock market kicked off ...

Hims & Hers stock fell by 27% as it announced plans to stop selling commercially available compounded semaglutide. The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales ...

Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...

Hims & Hers Health's stock has surged 205% since my last 'Buy' rating, but its valuation is now stretched, prompting a downgrade to 'Hold'. Some risks include Amazon's aggressive telehealth entry ...